NPF Statement on the FDA Approval of the Neupro® Patch

Release date: 4/3/2012

NPF Statement on the FDA Approval of the Neupro® Patch

"It is terrific news for the Parkinson's disease community that the Rotigotine patch has been re-approved. Because Parkinson's disease patients typically have to take many doses of medications each day, the re-approval of the patch will hopefully help a lot of sufferers."
— Dr. Michael S. Okun, National Medical Director of the National Parkinson Foundation

Excerpt from the UCB press release:

Neupro® approved by U.S. FDA for Parkinson’s Disease and Restless Legs Syndrome
April 3, 2012 – UCB announced today that the U.S. Food and Drug Administration (FDA) approved Neupro® (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson’s disease (PD) and as a treatment for moderate-to-severe primary Restless Legs Syndrome (RLS). Neupro® was previously approved by the FDA for the signs and symptoms of early stage idiopathic PD. Neupro® is a dopamine agonist patch that provides continuous drug delivery for patients with PD and RLS. The FDA has also approved UCB’s new formulation of Neupro®.

Read the full press release from UCB.

Print